ELOVL4
Reaktivität: Human
ELISA
Wirt: Kaninchen
Polyclonal
HRP
Applikationshinweise
Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-1:2000,ELISA 1:40000,Not yet tested in other applications.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
Liquid in PBS containing 50 % glycerol, 0.5 % BSA and 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C
Informationen zur Lagerung
Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
Haltbarkeit
12 months
Target
ELOVL4
(ELOVL Fatty Acid Elongase 4 (ELOVL4))
Andere Bezeichnung
ELOVL4
Hintergrund
ELOVL4, Elongation of very long chain fatty acids protein 4, 3-keto acyl-CoA synthase ELOVL4, ELOVL fatty acid elongase 4, ELOVL FA elongase 4ELOVL4 encodes a membrane-bound protein which is a member of the ELO family, proteins which participate in the biosynthesis of fatty acids. Consistent with the expression of the encoded protein in photoreceptor cells of the retina, mutations and small deletions in ELOVL4 are associated with Stargardt-like macular dystrophy (STGD3) and autosomal dominant Stargardt-like macular dystrophy (ADMD), also referred to as autosomal dominant atrophic macular degeneration.